CoChat

Pleiotropic Effects of GIP on Islet Function Involve Osteopontin

Open access
Lyssenko, Valeriya, Eliasson, Lena, Kotova, Olga, Pilgaard, Kasper, Wierup, Nils, Salehi, Albert, Wendt, Anna, Jonsson, Anna, De Marinis, Yang Z., Berglund, Lisa M., Taneera, Jalal, Balhuizen, Alexander, Hansson, Ola, Osmark, Peter, Dunér, Pontus, Brøns, Charlotte, Stančáková, Alena, Kuusisto, Johanna, Bugliani, Marco, Saxena, Richa, Ahlqvist, Emma, Kieffer, Timothy J., Tuomi, Tiinamaija, Isomaa, Bo, Melander, Olle, Sonestedt, Emily, Orho-Melander, Marju, Nilsson, Peter, Bonetti, Sara, Bonadonna, Riccardo, Miccoli, Roberto, DelPrato, Stefano, Marchetti, Piero, Madsbad, Sten, Poulsen, Pernille, Vaag, Allan, Laakso, Markku, Gomez, Maria F., Groop, Leif · 2011 · Diabetes
Cited by 98

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The incretin hormone GIP (glucose-dependent insulinotropic polypeptide) promotes pancreatic β-cell function by potentiating insulin secretion and β-cell proliferation. Recently, a combined analysis of several genome-wide association studies (Meta-analysis of Glucose and Insulin-Related Traits Consortium [MAGIC]) showed association to postprandial insulin at the GIP receptor (GIPR) locus. Here we explored mechanisms that could explain the protective effects of GIP on islet function. RESEARCH DESIGN AND METHODS: Associations of GIPR rs10423928 with metabolic and anthropometric phenotypes in both nondiabetic (N = 53,730) and type 2 diabetic individuals (N = 2,731) were explored by combining data from 11 studies. Insulin secretion was measured both in vivo in nondiabetic subjects and in vitro in islets from cadaver donors. Insulin secretion was also measured in response to exogenous GIP. The in vitro measurements included protein and gene expression as well as measurements of β-cell viability and proliferation. RESULTS: The A allele of GIPR rs10423928 was associated with impaired glucose- and GIP-stimulated insulin secretion and a decrease in BMI, lean body mass, and waist circumference. The decrease in BMI almost completely neutralized the effect of impaired insulin secretion on risk of type 2 diabetes. Expression of GIPR mRNA was decreased in human islets from carriers of the A allele or patients with type 2 diabetes. GIP stimulated osteopontin (OPN) mRNA and protein expression. OPN expression was lower in carriers of the A allele. Both GIP and OPN prevented cytokine-induced reduction in cell viability (apoptosis). In addition, OPN stimulated cell proliferation in insulin-secreting cells. CONCLUSIONS: These findings support β-cell proliferative and antiapoptotic roles for GIP in addition to its action as an incretin hormone. Identification of a link between GIP and OPN may shed new light on the role of GIP in preservation of functional β-cell mass in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db10-1532

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 98

Metadata

Authors
Lyssenko, V., Eliasson, L., Kotova, O., Pilgaard, K., Wierup, N., Salehi, A., Wendt, A., Jonsson, A., De Marinis, Y. Z., Berglund, L. M., Taneera, J., Balhuizen, A., Hansson, O., Osmark, P., Dunér, P., Brøns, C., Stančáková, A., Kuusisto, J., Bugliani, M., Saxena, R., Ahlqvist, E., Kieffer, T. J., Tuomi, T., Isomaa, B., Melander, O., Sonestedt, E., Orho-Melander, M., Nilsson, P., Bonetti, S., Bonadonna, R., Miccoli, R., DelPrato, S., Marchetti, P., Madsbad, S., Poulsen, P., Vaag, A., Laakso, M., Gomez, M. F., & Groop, L.
Venue
Diabetes
Published
2011-08-20
Volume
60
Issue
9
Pages
2424-2433
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2133754637
Cited by
98
References
9
FWCI
9.64
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.